SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending following the finalization of its $250 million acquisition of Ask Sage, a key generative AI platform for secure defense and government applications. This strategic move is driving significant bullish sentiment among investors who anticipate new government and TSA contracts, reinforcing its position in the AI defense sector. However, ongoing discussions and repeatedly postponed votes concerning increased authorized shares are causing investor debate, contributing to the stock's notable volatility.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics is trending due to its exceptionally low public float, positioning it as a prime candidate for a short squeeze. The community is actively discussing the company's significant cash reserves relative to its market valuation, fueling speculation about potential strategic alternatives like a merger. Many believe this combination of factors points to substantial untapped value and potential for rapid upward movement, drawing comparisons to other recent parabolic movers.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is actively trending as investors anticipate a potential housing market rebound in early 2026, driven by lower interest rates and the "January effect" for small-cap tech. Community sentiment is divided, with bulls optimistic about the company's strategic shift towards AI-powered real estate and its battle-tested leadership, while skeptics question past performance and the long-term profitability of its business model.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending following its announcement of record December and Q4 2025 vehicle deliveries, surpassing key competitors. The community is buzzing with speculation about whether these strong delivery figures will finally translate into profitability in Q4 or 2026, and if the stock price will reflect the improving fundamentals amid ongoing frustration over perceived market manipulation. Many highlight the expanding battery swap network and multi-brand strategy as crucial long-term growth drivers.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending due to extreme recent volatility, including a significant price drop from earlier highs, which is happening alongside news of its blockchain technology expanding into luxury and fashion traceability. Community sentiment is sharply divided, with proponents highlighting its disruptive tech and potential for a short squeeze amidst a low float and high cost to borrow, while skeptics point to a history of reverse splits and ongoing dilution concerns.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies (BMNR) is trending due to intense community debate surrounding an upcoming shareholder meeting, where a significant increase in authorized shares is a key proposal, fueling investor concerns over potential dilution and perceived management self-interest given the stock's underperformance against Ethereum. While some investors view recent declines as a buying opportunity, anticipating future staking revenue and a broader market rebound, many others express strong bearish sentiment, criticizing leadership actions and questioning the company's financial strategy.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions Inc. is trending after announcing a strategic manufacturing partnership and a private placement that is expected to strengthen its balance sheet and scale production. This has ignited intense community discussion, with many anticipating a short squeeze fueled by its low public float, while others express caution regarding potential dilution from the private placement.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire is trending as the community highlights its recent contract wins, including a significant European commercial space deal, and its diversified role across space infrastructure and defense systems. Many investors are actively discussing short squeeze potential and perceive the company as significantly undervalued, anticipating substantial long-term growth within the burgeoning space sector.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as investors eagerly await its Q4 delivery numbers, a key data point expected to drive significant price action. Bulls are anticipating strong growth from the energy division and future robotaxi deployments, while bears point to slowing EV sales, unfulfilled autonomy promises, and an elevated valuation, fueling a heated debate over the stock's direction.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending with intense community focus on an anticipated "Clarity Act" and potential supply shock, alongside recent developments like XRP ETF inflows and expanded institutional partnerships. While many foresee substantial price surges driven by these catalysts, there's also ongoing debate and frustration regarding its past price stagnation and the implications of Ripple's scheduled escrow releases.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 4.4% - Here's Why

Tiziana Life Sciences (NASDAQ:TLSA) Shares Down 4.4% - Should You Sell...

Tiziana Life Sciences (NASDAQ:TLSA) Shares Down 4.5% - Here's Why

Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 4.5% - Here's What Happened...

Nasdaq-listed shares of Tiziana Life Sciences (TLSA) rose 2% by Thursday afternoon after the company announced that it will advance its second asset, TZLS-501, and pursue non-dilutive funding strategies for its development.TZLS-501 is a fully human anti-IL-6 receptor monoclonal antibody or a biological therapy that blocks the action of interleukin-6 protein. Tiziana <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tizianalifesciences.com/news-releases/news-release-details/tiziana-advance-tzls-501-its-fully-human-il-6r-monoclonal">sees</a> potential to develop it as a monotherapy or in combination with its lead candidate, as well as with other anti-inflammatory and anti-infective agents.The company stated that TZLS-501 may offer therapeutic advantages in managing acute and chronic inflammatory conditions where excessive IL-6 signaling plays a central role, such as rheumatoid arthritis (RA), acute respiratory distress syndrome (ARDS), idiopathic pulmonary fibrosis (IPF), systemic lupus erythematosus, and various types of cancer.The company also stated that it will continue to advance intranasal Foralumab as its lead program, not diverting resources or focus from it. The firm is currently evaluating Foralumab in the treatment of multiple sclerosis, a chronic autoimmune disease in which the immune system attacks the protective myelin sheath surrounding nerve cells in the brain and spinal cord, causing numbness, vision problems, muscle weakness, balance issues, and fatigue.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TLSA">TLSA stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:573/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_25_at_1_37_07_PM_png_487989b630.webp" alt="TLSA's Sentiment Meter and Message Volume as of 1:37 p.m. ET on Sept. 25, 2025 | Source: Stocktwits" width="573" height="66"><figcaption>TLSA's Sentiment Meter and Message Volume as of 1:37 p.m. ET on Sept. 25, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes that the stock has “so much potential.”<stembedurl>https://stocktwits.com/GoCubsGo1124/message/629975723</stembedurl>Tiziana said on Thursday that the <a href="https://stocktwits.com/news-articles/markets/equity/tourmaline-stock-rockets-pre-market-after-novartis-buy-out-announcement/chwKP7BRdt5">recent acquisition</a> of Tourmaline Bio by Novartis for about $1.4 billion validates the importance of IL-6 therapeutics. The acquisition, announced earlier in September, includes Tourmaline’s Pacibekitug, a monoclonal antibody that targets IL-6, which is being evaluated as a treatment option for atherosclerotic cardiovascular disease.“With recent market developments, we feel it is an opportune time to explore TZLS-501’s development,” said Tiziana CEO Ivor Elrifi.TLSA stock nearly tripled in value this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-terminates-study-of-bimagrumab-in-obesity/chDlEmYR34I">Eli Lilly Terminates A Study Of Bimagrumab In Obesity</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Tiziana Life Sciences Shares Rise On Advancing Second Asset Besides Foralumab: Retail Thinks Stock Has ‘So Much Potential’

Tiziana said that TZLS-501 may offer therapeutic advantages in managing acute and chronic inflammatory conditions.

Equity

Tiziana said that TZLS-501 may offer therapeutic advantages in managing acute and chronic inflammatory conditions.


AIM ImmunoTech, Inc. (1100% jump in message volume)AIM ImmunoTech surged in retail discussions after announcing the first new subject was dosed in Phase 2 of its Phase 1b/2 trial for Ampligen and AstraZeneca’s (AZN) Imfinzi in late-stage pancreatic cancer treatment. Several Phase 1 patients who received the highest dose will also be included in Phase 2. The trial, known as DURIPANC, is taking place in the Netherlands and will enroll up to 25 patients in this phase.PepGen, Inc. (700% jump in message volume)PepGen shares and retail chatter <a href="https://stocktwits.com/news-articles/markets/equity/pepgen-stock-heads-for-best-week-since-sept-2022/chdghv2RyH">soared</a> after the company released early clinical data from its FREEDOM-DM1 Phase 1 trial for PGN-EDODM1 in myotonic dystrophy type 1 (DM1), a genetic disorder causing progressive muscle weakness. The company reported dose-dependent splicing correction of 12.3% at 5 mg/kg and 29.1% at 10 mg/kg at 28 days post-dosing.While single-dose studies haven’t shown functional improvements, PepGen sees early signs of benefits with repeat dosing. H.C. Wainwright called the data “very encouraging.”Aeon Biopharma, Inc. (700% jump in message volume)Aeon gained attention after announcing a 1-for-72 reverse stock split to meet NYSE American’s minimum share price requirement. The move took effect on Wednesday, with fractional shares rounded up.Last month, Aeon received a non-compliance notice from NYSE American for failing to meet the $2 million stockholders’ equity requirement. The company reported a $32.1 million stockholders’ deficit as of Sept. 30 and has suffered losses in its last two fiscal years. Aeon has until March 5 to submit a plan to regain compliance.Tiziana Life Sciences Ltd. (600% jump in message volume)Tiziana’s stock buzz jumped after a Nature Neuroscience study showed its nasal anti-CD3 monoclonal antibody significantly reduced neuroinflammation and improved recovery in a preclinical model of traumatic brain injury (TBI). The treatment correlated with less anxiety, reduced cognitive decline, and improved motor skills.Additionally, Tiziana revealed on Tuesday that its nasal anti-CD3 preclinical study is nearing completion and that foralumab could be a novel treatment for long COVID.Moleculin Biotech, Inc.&nbsp;(600% jump in message volume)Moleculin saw heightened retail discussion after announcing a $1.07 per share direct offering of about 3.3 million shares and warrants to an institutional investor, with 6.5 million warrants exercisable at $1.07 per share for five years.The company&nbsp;expected to close the offering on Feb. 26, with Roth Capital Partners as the placement agent. The company said proceeds would be used for working capital and general corporate purposes.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in developing therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Alzheimer’s. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.

TLSA
Tiziana Life Sciences Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TLSA News

TLSATiziana Life Sciences Ltd